Lilly strikes $8.8bn-plus alliance with China's Innovent Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

#EliLilly has deepened its ties with #Chinesebiopharma company #InnoventBiologics, signing a seventh R&D #collaboration that includes a $350 million upfront payment.

pharmaphorum.com/news/lilly-s...